Small peptides: chemistry, biology and clinical studies
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Amsterdam u.a.
Elsevier
1993
|
| Schriftenreihe: | Pharmacochemistry library
19 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XVI, 616 S. |
| ISBN: | 0444886559 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV008895086 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 940221s1993 |||| 00||| engod | ||
| 020 | |a 0444886559 |9 0-444-88655-9 | ||
| 035 | |a (OCoLC)28498594 | ||
| 035 | |a (DE-599)BVBBV008895086 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 050 | 0 | |a QP572.P4 | |
| 082 | 0 | |a 612/.015746 |2 20 | |
| 084 | |a VK 8560 |0 (DE-625)147540:253 |2 rvk | ||
| 100 | 1 | |a Dutta, Anand S. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Small peptides |b chemistry, biology and clinical studies |c A. S. Dutta |
| 264 | 1 | |a Amsterdam u.a. |b Elsevier |c 1993 | |
| 300 | |a XVI, 616 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Pharmacochemistry library |v 19 | |
| 650 | 4 | |a Hormones | |
| 650 | 4 | |a Neuropeptides |x Agonists | |
| 650 | 4 | |a Neuropeptides |x Antagonists | |
| 650 | 4 | |a Neuropeptides |x antagonists & inhibitors | |
| 650 | 4 | |a Peptide hormones |x Agonists | |
| 650 | 4 | |a Peptide hormones |x Antagonists | |
| 650 | 4 | |a Peptides |x antagonists & inhibitors | |
| 650 | 4 | |a Protein drugs | |
| 650 | 4 | |a Proteins |x therapeutic use | |
| 650 | 4 | |a Receptors, Peptide | |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Peptidhormon |0 (DE-588)4045127-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Neuropeptide |0 (DE-588)4041895-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Antagonist |0 (DE-588)4198647-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Peptide |0 (DE-588)4045125-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Neuropeptide |0 (DE-588)4041895-9 |D s |
| 689 | 0 | 1 | |a Antagonist |0 (DE-588)4198647-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Peptide |0 (DE-588)4045125-2 |D s |
| 689 | 1 | 1 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Peptidhormon |0 (DE-588)4045127-6 |D s |
| 689 | 2 | 1 | |a Antagonist |0 (DE-588)4198647-7 |D s |
| 689 | 2 | |5 DE-604 | |
| 830 | 0 | |a Pharmacochemistry library |v 19 |w (DE-604)BV001899371 |9 19 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005885703&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-005885703 | ||
Datensatz im Suchindex
| _version_ | 1804123253516533760 |
|---|---|
| adam_text | 0 PHARMACOCHEMISTRY LIBRARY EDITOR: H. TIMMERMAN VOLUME 19 SMALL
PEPTIDES CHEMISTRY, BIOLOGY AND CLINICAL STUDIES A.S. DUTTA COMPANY
RESEARCH ASSOCIATE ZENECA PHARMACEUTICALS ALDER LEY PARK, MACCLESFIELD
CHESHIRE SKI0 4TG, U.K. ELSEVIER - AMSTERDAM - LONDON - NEW YORK - TOKYO
1993 .T. V VII CONTENTS ACKNOWLEDGEMENTS XVI INTRODUCTION 1 CHAPTER 1
ANGIOTENSIN II 1. INTRODUCTION 9 2. RECEPTOR SUBTYPES OF ANGIOTENSIN II
9 3. AGONIST ANALOGUES OF ANGIOTENSIN II 15 4. PEPTIDE ANTAGONISTS OF
ANGIOTENSIN II 16 4.1. MODIFICATIONS OF THE C-TERMINAL PHE RESIDUE 16
4.2. REPLACEMENT OF THE TYR 4 RESIDUE 19 4.3. N- ORC-TERMINAL DELETIONS
20 4.4. INTERCHANGING THE TYR 4 AND PHE^ RESIDUES 20 5. NON-PEPTIDE
ANTAGONISTS OF ANGIOTENSIN II 21 5.1. MODIFICATIONS OF THE EARLY
IMIDAZOLE LEADS 21 5.2. LMIDAZOLE-5-ACRYLIC ACID DERIVATIVES AS
ANTAGONISTS OF ANGIOTENSIN II 28 5.3. LMIDAZO[4,5-B]PYRIDINE DERIVATIVES
AS ANTAGONISTS OF ANGIOTENSIN II 31 5.4. 2-ALKYL BENZIMIDAZOLE
DERIVATIVES AS ANTAGONISTS OF ANGIOTENSIN II 31 5.5.
2-ALKYL-4-(BIPHENYL)METHOXYQUINOLINE AND 2,6-DIALKYL-4-(BIPHENYL)-
METHOXY PYRIDINE DERIVATIVES AS ANTAGONISTS OF ANGIOTENSIN II 32 5.6.
NAPHTHALENE, TETRAHYDRONAPHTHALENE, BROMOINDOLE AND BROMOBENZOFURAN
DERIVATIVES AS ANTAGONISTS OF ANGIOTENSIN II 43 5.7. ANGIOTENSIN
ANTAGONISTS CONTAINING AN AMINOMETHYLENE BRIDGE 44 6. NON-PEPTIDE
ANTAGONISTS OF ANGIOTENSIN II ACTING AT THE AT2 RECEPTOR 44 7. SUMMARY
54 8. REFERENCES 60 CHAPTER 2 BOMBESIN/GASTRIN-RELEASING PEPTIDE 1.
INTRODUCTION 66 2. ANTAGONISTS OF BOMBESIN/GRP 68 2.1 DELETION OF THE
C-TERMINAL METHIONINE RESIDUE OR THE DIPEPTIDE LEUCYLMETHIONINE 68 2.2
MODIFICATION OF THE BACKBONE AMIDE GROUPS 73 VIII 2.3 AMINO ACID
SUBSTITUTIONS IN POSITION 12 74 2.4 SUBSTANCE P ANTAGONISTS AS BOMBESIN
ANTAGONISTS 74 3. CONFORMATIONALLY RESTRICTED ANALOGUES OF BOMBESIN 75
4. BOMBESIN/GRP ANTAGONISTS AND CANCER 76 5. SUMMARY 78 6. REFERENCES 80
CHAPTER 3 BRADYKININ ANALOGUES 1. INTRODUCTION 83 2. RECEPTOR SUBTYPES
OF BRADYKININ 84 3. AGONIST ANALOGUES OF BRADYKININ 84 4. ANTAGONISTS OF
BRADYKININ 85 4.1. BI RECEPTOR ANTAGONISTS 85 4.2. BI AND B2 RECEPTOR
ANTAGONISTS 89 4.2.1. ANTAGONISTS CONTAINING A D-PHE RESIDUE IN POSITION
7 89 4.2.2. ANTAGONISTS OF BRADYKININ CONTAINING CONFORMATIONALLY
RESTRICTED AMINO ACID RESIDUES IN POSITIONS 7 AND 8 91 5. BIOLOGICAL
PROFILE OF HOE 140 AND RELATED ANTAGONISTS 91 5.1. IN VITRO STUDIES 97
5.2. IN VIVO STUDIES 98 6. SIDE EFFECTS ASSOCIATED WITH BRADYKININ
ANTAGONISTS 99 7. SUMMARY 99 8. REFERENCES 100 CHAPTER 4 CHOLECYSTOKININ
ANALOGUES 1. INTRODUCTION 104 2. DISTRIBUTION AND BIOLOGICAL FUNCTIONS
OF CHOLECYSTOKININ .105 3. CHOLECYSTOKININ RECEPTOR SUBTYPES AND
RECEPTOR- SELECTIVE LIGANDS 106 3.1. CCK-A RECEPTOR LIGANDS 107 3.2.
CCK-B RECEPTOR LIGANDS 114 4. PEPTIDE ANTAGONISTS OF CHOLECYSTOKININ AND
GASTRIN 118 4.1. CHOLECYSTOKININ AND GASTRIN ANTAGONISTS BASED ON THE
CCK SEQUENCE ....118 4.2. ANTAGONISTS BASED ON THE GASTRIN C-TERMINAL
SEQUENCE 122 4.3. ANTAGONISTS OBTAINED BY PEPTIDE BOND REPLACEMENTS 123
4.4. ANTAGONISTS CONTAINING A HOMO AMINO ACID RESIDUE 124 4.5. OTHER
APPROACHES TO ANTAGONISTS 124 IX 5. NON-PEPTIDE ANTAGONISTS OF CCK AND
GASTRIN 125 5.1. AMINO ACID DERIVATIVES AS CCK AND GASTRIN ANTAGONISTS
125 5.2. SUBSTITUTED BENZODIAZEPINES AS CCK AND GASTRIN ANTAGONISTS 129
5.3. 3-SUBSTITUTED-1,4-BENZODIAZEPINES AS CCK ANTAGONISTS 129 5.3.1.
3-ALKYL SERIES OF ANALOGUES 129 5.3.2. 3-AMIDO SERIES OF ANALOGUES AS
CCK-A SELECTIVE LIGANDS 130 5.3.3. 3-UREA SERIES OF ANALOGUES AS
SELECTIVE CCK-B/GASTRIN RECEPTOR LIGANDS 137 5.4. CCK-A RECEPTOR LIGANDS
BASED ON TIFLUADOM 140 5.5. HYBRID CCK ANTAGONISTS BASED ON LORGLUMIDE
AND L-364,718 (MK-329) ...140 5.6. OC-METHYLTRYPTOPHAN DERIVATIVES AS
CCK ANTAGONISTS 140 5.7. QUINAZOLINONE DERIVATIVES AS CCK-B RECEPTOR
LIGANDS 149 6. SUMMARY 149 7. REFERENCES 159 CHAPTER 5 ENKEPHALIN
ANALOGUES 1. INTRODUCTION 166 2. ENZYMIC INACT1VATION OF ENKEPHALINS 168
3. EARLY STRUCTURE ACTIVITY RELATIONSHIP STUDIES 168 4. AGONIST
ANALOGUES DISPLAYING ANALGESIC ACTIVITY 172 5. ANALOGUES WITH IMPROVED
SELECTIVITY FOR THE I AND 5 RECEPTORS 173 5.1. 8-SELECTIVE ANALOGUES
174 5.1.1 LINEAR PEPTIDES 174 5.1.2. CYCLIC PEPTIDES 176 5.2.
^.-SELECTIVE ANALOGUES 182 5.2.1. LINEAR PEPTIDES 182 5.2.2. CYCLIC
PEPTIDES 183 6. ANTAGONISTS OF ENKEPHALINS 189 6.1. 5-SELECTIVE
ANTAGONISTS BASED ON THE ENKEPHALIN SEQUENCE 189 6.2. ^-SELECTIVE
ANTAGONISTS OF ENKEPHALIN 193 6.2.1. ^.-SELECTIVE ANTAGONISTS BASED ON
THE ENKEPHALIN SEQUENCE 193 6.2.2. ^-SELECTIVE ANTAGONISTS OF ENKEPHALIN
BASED ON THE SOMATOSTATIN SEQUENCE 193 7. SUMMARY 194 8 REFERENCES 197
CHAPTER 6 LUTEINISING HORMONE RELEASING HORMONE 1. INTRODUCTION 203 2.
ENZYMIC DEGRADATION OF LHRH 205 3. SAR OF LHRH AGONISTS 206 3.1
BIOLOGICALLY ACTIVE ANALOGUES OF LHRH SMALLER THAN A DECAPEPTIDE 207 3.2
POTENT ANALOGUES OF LHRH INCORPORATING CHANGES IN POSITIONS 6, 7 AND 10
208 3.3 POTENT ANALOGUES OF LHRH INCORPORATING CC-AZA-AMINO-ACID
RESIDUES 218 3.4 POTENT ANALOGUES OF LHRH WITH HYDROPHILIC RESIDUES IN
POSITION 6 218 3.5 ANALOGUES OF LHRH CONTAINING NITROGEN MUSTARD
DERIVATIVES OR CYTOTOXIC METAL COMPLEXES 218 4. SAR OF LHRH ANTAGONISTS
219 4.1 SUMMARY OF THE EARLIER WORK 220 4.2 RECENT WORK ON LHRH
ANTAGONISTS 222 4.2.1 EFFECTS OF CHANGES IN POSITION 1 222 4.2.2 EFFECTS
OF CHANGES IN POSITION 2 228 4.2.3 EFFECTS OF CHANGES IN POSITIONS 3 AND
4 228 4.2.4 EFFECTS OF CHANGES IN POSITION 5 232 4.2.5 EFFECTS OF
CHANGES IN POSITION 6 232 4.2.6 EFFECTS OF CHANGES IN POSITION 7 237
4.2.7 EFFECTS OF CHANGES IN POSITION 8 237 4.2.8 EFFECTS OF CHANGES IN
POSITION 10 244 4.2.9 CYCLIC ANALOGUES 252 5. LHRH ANTAGONISTS AND
HISTAMINE RELEASE 253 6. HEXAPEPTIDE DERIVATIVES AS LHRH ANTAGONISTS 25
5 7. KETACONAZOLE DERIVATIVES AS LHRH ANTAGONISTS 255 8. FORMULATIONS OF
LHRH AND THE ANALOGUES 257 9. PHARMACOLOGICAL AND CLINICAL STUDIES WITH
LHRH AGONISTS AND ANTAGONISTS 258 9.1 USE OF LHRH AGONISTS FOR THE
TREATMENT OF PROSTATE CANCER 258 9.2 USE OF LHRH ANTAGONISTS FOR THE
TREATMENT OF PROSTATE CANCER 262 9.3 USE OF LHRH AGONISTS FOR THE
TREATMENT OF BREAST CANCER 263 9.4 USE OF LHRH ANTAGONISTS FOR THE
TREATMENT OF BREAST CANCER 265 9.5 USE OF LHRH AGONISTS AND ANTAGONISTS
IN ENDOMETRIOSIS 266 9.6 LHRH AGONISTS FOR THE TREATMENT OF UTERINE
FIBROIDS (LEIOMYOMATA) 266 9.7 LHRH AGONISTS AS MALE CONTRACEPTIVES 267
9.8 LHRH ANTAGONISTS AS MALE CONTRACEPTIVES 268 XI 9.9 LHRH AGONISTS AS
FEMALE CONTRACEPTIVES 269 9.10. LHRH ANTAGONISTS AS FEMALE
CONTRACEPTIVES 271 10. SUMMARY 273 11. REFERENCES 281 CHAPTER 7
SOMATOSTATIN 1. INTRODUCTION 293 2. ENZYMIC DEGRADATION OF SOMATOSTATIN
AND ANALOGUES 293 3. AGONIST ANALOGUES OF SOMATOSTATIN. SAR STUDIES 295
3.1 ROLE OF THE DISULPHIDE BRIDGE AND THE N-TERMINAL ALA-GLY RESIDUES
295 3.2 EFFECTS OF SINGLE AMINO ACID SUBSTITUTIONS ON THE BIOLOGICAL
ACTIVITY OF SOMATOSTATIN 296 3.3 EFFECTS OF N-TERMINAL EXTENSION AND
MULTIPLE SUBSTITUTIONS ON THE BIOLOGICAL ACTIVITY OF SOMATOSTATIN 308
3.4 CYCLIC DODECAPEPTIDE ANALOGUES WITH AMINO ACID DELETIONS AND
DISULPHIDE BRIDGE MODIFICATIONS 309 3.5 BICYCLIC DECAPEPTIDE AND CYCLIC
HEXAPEPTIDE ANALOGUES 310 3.6 LINEAR AND CYCLIC OCTAPEPTIDE ANALOGUES
332 3.7 SOMATOSTATIN ANALOGUES AS OPIATE (^-RECEPTOR) ANTAGONISTS 333 4.
CLINICAL APPLICATIONS OF SOMATOSTATIN ANALOGUES 342 4.1 PITUITARY
TUMOURS 342 4.2 PANCREATIC TUMOURS 343 4.3 BREAST CANCER 344 4.4
PROSTATE CANCER 344 4.5 LUNG CANCER 345 4.6 MECHANISM OF TUMOUR GROWTH
INHIBITION 346 4.6.1 EXISTENCE OF SOMATOSTATIN RECEPTORS IN TUMOUR CELLS
346 4.6.2 ROLE OF SOMATOSTATIN IN DEPHOSPHORYLATION OF THE GROWTH FACTOR
(EGF) INDUCED PHOSPHORYLATED TYROSINE KINASE 347 5. SUMMARY 348 6.
REFERENCES 350 CHAPTER 8 TACHYKININS SUBSTANCE P, NEUROKININ A AND
NEUROKININ B 1. INTRODUCTION 356 2. RECEPTOR SUBTYPES OF TACHYKININS 357
XII 2.1 RECEPTOR CLASSIFICATION BASED ON TACHYKININS 358 2.2 RECEPTOR
CLASSIFICATION BASED ON TACHYKININ FRAGMENTS 360 2.3 RECEPTOR
CLASSIFICATION BASED ON TACHYKININ ANTAGONISTS 360 3. SAR OF THE
MAMMALIAN TACHYKININS 361 3.1 SAR OF THE C-TERMINAL FRAGMENTS 362 3.2
EFFECTS OF AMINO ACID SUBSTITUTIONS IN SUBSTANCE P 363 3.3 ANALOGUES OF
SUBSTANCE P MORE SELECTIVE AT THE NK-1 RECEPTOR 365 3.4 AGONIST
ANALOGUES OF NEUROKININ A AND NEUROKININ B 369 3.4.1 NKA ANALOGUES 369
3.4.2 NKB ANALOGUES 373 4. ANTAGONISTS OF SUBSTANCE P 375 4.1
ANTAGONISTS BASED ON THE UNDECAPEPTIDE SEQUENCE 375 4.2 ANTAGONISTS
BASED ON THE C-TERMINAL FRAGMENTS 379 4.3. TRIPEPTIDE DERIVATIVES AS
ANTAGONISTS OF SP 380 5. ANTAGONISTS OF NEUROKININ A AND NEUROKININ B
384 6. NON-PEPTIDE ANTAGONISTS OF THE TACHYKININS 386 6.1. CP-96,345
SERIES OF SUBSTANCE P ANTAGONISTS 386 6.2. LMIDAZO[4,5-B]QUINOXALINE
SERIES OF TACHYKININ ANTAGONISTS 388 6.3. NAPHTHIMIDAZOLIUM DERIVATIVES
AS TACHYKININ ANTAGONISTS 388 6.4. PERHYDROISOINDOLE AND
ANDROSTANO[3,2-B]PYRIMIDO[1,2-A]BENZIMIDAZOLES AS TACHYKININ ANTAGONISTS
388 6.5 SR 48968, AN NK-2 RECEPTOR ANTAGONIST 389 6.6. NK-1 AND NK-2
SELECTIVE ANTAGONISTS OBTAINED FROM NATURAL PRODUCTS 398 7. BIOLOGICAL
STUDIES USING SP ANALOGUES 398 7.1 SP ANTAGONISTS AS ANALGESICS 398 7.2
SP ANTAGONISTS IN NEUROGENIC INFLAMMATION 399 7.3 SP ANTAGONISTS IN
NEUROGENIC BRONCHOCONSTRICTION 400 7.4 SP AND SALIVARY SECRETION 401 7.5
SP ANTAGONISTS IN SMALL-CELL CARCINOMA OF THE LUNG 401 7.6 SP AND
HISTAMINE RELEASE 402 7.7 OTHER BIOLOGICAL EFFECTS ASSOCIATED WITH SP
ANTAGONISTS. SIDE-EFFECTS? 402 8. SUMMARY 403 9. REFERENCES 406 CHAPTER
9 INHIBITORS OF ASPARTYL PROTEASES. 1. RENIN 1. INTRODUCTION 416 2.
INHIBITORS OF RENIN 416 2.1. INHIBITORS BASED ON THE RENIN SUBSTRATE 417
2.2. SUBSTRATE BASED INHIBITORS OF RENIN CONTAINING A MODIFIED SCISSILE
PEPTIDE BOND 418 XIII 2.2.1. REPLACEMENT OF THE SCISSILE PEPTIDE BOND BY
A P(CH2-NH) GROUP 418 2.2.2. REPLACEMENT OF THE SCISSILE PEPTIDE BOND
BY A Y(CH0H-CH2) GROUP ..422 2.2.3. REPLACEMENT OF THE SCISSILE PEPTIDE
BOND BY A X F(P(O)(OH)-CH2) GROUP 423 2.3. INHIBITORS CONTAINING A
STATINE RESIDUE IN THE PI POSITION 423 2.4. APPROACHES DESIGNED TO
IMPROVE POTENCY, STABILITY, ORAL ACTIVITY AND DURATION OF ACTION OF THE
RENIN INHIBITORS 426 2.4.1. C-TERMINAL MODIFICATIONS IN PEPTIDES
CONTAINING A MODIFIED SCISSILE PEPTIDE BOND 427 2.4.2. N- AND C-TERMINAL
MODIFICATIONS IN PEPTIDES CONTAINING A MODIFIED SCISSILE PEPTIDE BOND
428 2.4.3. INCORPORATION OF UNNATURAL AMINO ACIDS 428 2.4.4. CHANGES IN
THE PHE-HIS (P3-P2) RESIDUES 433 2.4.5. MULTIPLE SUBSTITUTIONS IN RENIN
INHIBITORS 436 2.4.6. CONFORMATIONALLY RESTRICTED INHIBITORS OF RENIN
456 2.5. INHIBITORS OF RENIN UNRELATED TO THE ANGIOTENSINOGEN SEQUENCE
468 2.6. INHIBITORS OF RENIN ISOLATED FROM NATURAL PRODUCTS 469 3.
SUMMARY 469 4. REFERENCES 475 CHAPTER 10 INHIBITORS OF ASPARTYL
PROTEASES. 2. HIV PROTEASE 1. INTRODUCTION 482 2. NATURE OF THE ENZYME
483 3. CHEMICAL APPROACHES USED IN THE DESIGN OF INHIBITORS 483 3.1.
SUBSTRATE ANALOGUES CONTAINING A MODIFIED SCISSILE PEPTIDE BOND 484 3.2.
INHIBITORS OF HIV PROTEASE CONTAINING A HYDROXYMETHYLCARBONYL ISOSTERE
486 3.3. INHIBITORS OF HIV PROTEASE CONTAINING A HYDROXYETHYLAMINE GROUP
486 3.4. INHIBITORS OF HIV PROTEASE CONTAINING A HYDROXYETHYLENE
ISOSTERE 500 3.5. INHIBITORS OF HIV PROTEASE CONTAINING A
DIHYDROXYETHYLENE ISOSTERE 505 3.6. DIMERIC INHIBITORS OF HIV PROTEASE
510 4 NON-PEPTIDE INHIBITORS OF HIV PROTEASE 515 5. SUMMARY 515 6.
REFERENCES 520 XIV CHAPTER 11 METALLOPEPTIDASE (ACE, ENKEPHALINASE AND
ATRIOPEPTIDASE) INHIBITORS 1. INTRODUCTION 525 2. INHIBITORS OF
ANGIOTENSIN CONVERTING ENZYME 526 2.1 ACE INHIBITORS WITH A THIOL
FUNCTION AS A CHELATING GROUP 527 2.2 ACE INHIBITORS CONTAINING A
CARBOXYL FUNCTION 531 2.3 PHOSPHORUS CONTAINING INHIBITORS OF ACE 540
2.4 GLUTAMIC ACID DERIVATIVES AS INHIBITORS OF ACE 543 2.5 INHIBITORS OF
ACE ISOLATED FROM NATURAL PRODUCTS 547 3. INHIBITORS OF ENKEPHALIN
DEGRADING DIPEPTIDYL- CARBOXYPEPTIDASE (ENKEPHALINASE) 547 3.1
PROPERTIES OF ENKEPHALINASE 548 3.2 DESIGN OF ENKEPHALINASE INHIBITORS
549 3.2.1 THIOL-CONTAINING INHIBITORS OF ENKEPHALINASE 549 3.2.2
CARBOXYALKYL DERIVATIVES AS ENKEPHALINASE INHIBITORS 550 3.2.3
HYDROXAMIC ACID DERIVATIVES AS ENKEPHALINASE INHIBITORS 556 3.2.4 OTHER
INHIBITORS OF ENKEPHALINASE 558 3.3 ANALGESIC EFFECTS OF THE
ENKEPHALINASE INHIBITORS 558 4. INHIBITORS OF ATRIAL NATR1URETIC FACTOR
(ANF) DEGRADING ENZYME 561 4.1. DESIGN OF THE INHIBITORS 563 4.2.
BIOLOGICAL AND CLINICAL EVALUATIONS OF THE ANF DEGRADING
METALLO-ENDOPEPTIDASE INHIBITORS 568 5. SUMMARY 571 6. REFERENCES 575
CHAPTER 12 FORMULATION OF PEPTIDES 1. INTRODUCTION 583 2. POLYMERIC
CONTROLLED DRUG DELIVERY SYSTEMS (DEPOT FORMULATIONS) 584 2.1. DEPOT
FORMULATIONS OF LHRH ANALOGUES 585 2.2. DEPOT FORMULATIONS OF INSULIN
587 2.3. DEPOT FORMULATIONS OF OXYTOCIN AND VASOPRESSIN 587 2.4. DEPOT
FORMULATIONS OF GROWTH HORMONE RELEASING FACTOR AND CALCITONIN 588 3.
IMPROVEMENTS IN THE ORAL DELIVERY OF PEPTIDES 588 XV 4. INTRANASAL
ADMINISTRATION OF PEPTIDES 59 0 4.1. INTRANASAL FORMULATIONS OF LHRH
ANALOGUES 590 4.2. INTRANASAL FORMULATIONS OF INSULIN AND CALCITONIN 591
4.3. INTRANASAL FORMULATIONS OF ACTH, GROWTH HORMONE AND DESMOPRESSIN
592 5. TRANSDERMAL LONTOPHORETIC DRUG DELIVERY OF PEPTIDES 592 6.
ADMINISTRATION OF PEPTIDES BY OCULAR, VAGINAL AND RECTAL ROUTES 594 6.1.
OCULAR ABSORPTION OF PEPTIDES 594 6.2. VAGINAL ABSORPTION OF PEPTIDES
595 6.3. RECTAL ABSORPTION OF PEPTIDES 596 7. REFERENCES 596 SUBJECT
INDEX 602
|
| any_adam_object | 1 |
| author | Dutta, Anand S. |
| author_facet | Dutta, Anand S. |
| author_role | aut |
| author_sort | Dutta, Anand S. |
| author_variant | a s d as asd |
| building | Verbundindex |
| bvnumber | BV008895086 |
| callnumber-first | Q - Science |
| callnumber-label | QP572 |
| callnumber-raw | QP572.P4 |
| callnumber-search | QP572.P4 |
| callnumber-sort | QP 3572 P4 |
| callnumber-subject | QP - Physiology |
| classification_rvk | VK 8560 |
| ctrlnum | (OCoLC)28498594 (DE-599)BVBBV008895086 |
| dewey-full | 612/.015746 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 612 - Human physiology |
| dewey-raw | 612/.015746 |
| dewey-search | 612/.015746 |
| dewey-sort | 3612 515746 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02262nam a2200613 cb4500</leader><controlfield tag="001">BV008895086</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">940221s1993 |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0444886559</subfield><subfield code="9">0-444-88655-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)28498594</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV008895086</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP572.P4</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">612/.015746</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VK 8560</subfield><subfield code="0">(DE-625)147540:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dutta, Anand S.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Small peptides</subfield><subfield code="b">chemistry, biology and clinical studies</subfield><subfield code="c">A. S. Dutta</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam u.a.</subfield><subfield code="b">Elsevier</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVI, 616 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Pharmacochemistry library</subfield><subfield code="v">19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hormones</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuropeptides</subfield><subfield code="x">Agonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuropeptides</subfield><subfield code="x">Antagonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuropeptides</subfield><subfield code="x">antagonists & inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptide hormones</subfield><subfield code="x">Agonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptide hormones</subfield><subfield code="x">Antagonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peptides</subfield><subfield code="x">antagonists & inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Proteins</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Receptors, Peptide</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Peptidhormon</subfield><subfield code="0">(DE-588)4045127-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Neuropeptide</subfield><subfield code="0">(DE-588)4041895-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antagonist</subfield><subfield code="0">(DE-588)4198647-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Peptide</subfield><subfield code="0">(DE-588)4045125-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Neuropeptide</subfield><subfield code="0">(DE-588)4041895-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Antagonist</subfield><subfield code="0">(DE-588)4198647-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Peptide</subfield><subfield code="0">(DE-588)4045125-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Peptidhormon</subfield><subfield code="0">(DE-588)4045127-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Antagonist</subfield><subfield code="0">(DE-588)4198647-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Pharmacochemistry library</subfield><subfield code="v">19</subfield><subfield code="w">(DE-604)BV001899371</subfield><subfield code="9">19</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005885703&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-005885703</subfield></datafield></record></collection> |
| id | DE-604.BV008895086 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T17:26:50Z |
| institution | BVB |
| isbn | 0444886559 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-005885703 |
| oclc_num | 28498594 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XVI, 616 S. |
| publishDate | 1993 |
| publishDateSearch | 1993 |
| publishDateSort | 1993 |
| publisher | Elsevier |
| record_format | marc |
| series | Pharmacochemistry library |
| series2 | Pharmacochemistry library |
| spelling | Dutta, Anand S. Verfasser aut Small peptides chemistry, biology and clinical studies A. S. Dutta Amsterdam u.a. Elsevier 1993 XVI, 616 S. txt rdacontent n rdamedia nc rdacarrier Pharmacochemistry library 19 Hormones Neuropeptides Agonists Neuropeptides Antagonists Neuropeptides antagonists & inhibitors Peptide hormones Agonists Peptide hormones Antagonists Peptides antagonists & inhibitors Protein drugs Proteins therapeutic use Receptors, Peptide Arzneimittel (DE-588)4003115-9 gnd rswk-swf Peptidhormon (DE-588)4045127-6 gnd rswk-swf Neuropeptide (DE-588)4041895-9 gnd rswk-swf Antagonist (DE-588)4198647-7 gnd rswk-swf Peptide (DE-588)4045125-2 gnd rswk-swf Neuropeptide (DE-588)4041895-9 s Antagonist (DE-588)4198647-7 s DE-604 Peptide (DE-588)4045125-2 s Arzneimittel (DE-588)4003115-9 s Peptidhormon (DE-588)4045127-6 s Pharmacochemistry library 19 (DE-604)BV001899371 19 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005885703&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Dutta, Anand S. Small peptides chemistry, biology and clinical studies Pharmacochemistry library Hormones Neuropeptides Agonists Neuropeptides Antagonists Neuropeptides antagonists & inhibitors Peptide hormones Agonists Peptide hormones Antagonists Peptides antagonists & inhibitors Protein drugs Proteins therapeutic use Receptors, Peptide Arzneimittel (DE-588)4003115-9 gnd Peptidhormon (DE-588)4045127-6 gnd Neuropeptide (DE-588)4041895-9 gnd Antagonist (DE-588)4198647-7 gnd Peptide (DE-588)4045125-2 gnd |
| subject_GND | (DE-588)4003115-9 (DE-588)4045127-6 (DE-588)4041895-9 (DE-588)4198647-7 (DE-588)4045125-2 |
| title | Small peptides chemistry, biology and clinical studies |
| title_auth | Small peptides chemistry, biology and clinical studies |
| title_exact_search | Small peptides chemistry, biology and clinical studies |
| title_full | Small peptides chemistry, biology and clinical studies A. S. Dutta |
| title_fullStr | Small peptides chemistry, biology and clinical studies A. S. Dutta |
| title_full_unstemmed | Small peptides chemistry, biology and clinical studies A. S. Dutta |
| title_short | Small peptides |
| title_sort | small peptides chemistry biology and clinical studies |
| title_sub | chemistry, biology and clinical studies |
| topic | Hormones Neuropeptides Agonists Neuropeptides Antagonists Neuropeptides antagonists & inhibitors Peptide hormones Agonists Peptide hormones Antagonists Peptides antagonists & inhibitors Protein drugs Proteins therapeutic use Receptors, Peptide Arzneimittel (DE-588)4003115-9 gnd Peptidhormon (DE-588)4045127-6 gnd Neuropeptide (DE-588)4041895-9 gnd Antagonist (DE-588)4198647-7 gnd Peptide (DE-588)4045125-2 gnd |
| topic_facet | Hormones Neuropeptides Agonists Neuropeptides Antagonists Neuropeptides antagonists & inhibitors Peptide hormones Agonists Peptide hormones Antagonists Peptides antagonists & inhibitors Protein drugs Proteins therapeutic use Receptors, Peptide Arzneimittel Peptidhormon Neuropeptide Antagonist Peptide |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005885703&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV001899371 |
| work_keys_str_mv | AT duttaanands smallpeptideschemistrybiologyandclinicalstudies |